Apogee Therapeutics logo

Apogee TherapeuticsNASDAQ: APGE

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

14 July 2023

Next earnings report:

13 November 2024

Last dividends:

N/A

Next dividends:

N/A
$3.14 B
-21%vs. 3y high
86%vs. sector
-vs. 3y high
-vs. sector
-63%vs. 3y high
78%vs. sector
-vs. 3y high
-vs. sector

Price

pre-market | 16 min ago
$55.39+$0.90(+1.65%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

APGE Latest News

Apogee Therapeutics to Participate in Upcoming November Investor Conferences
globenewswire.com04 November 2024 Sentiment: -

SAN FRANCISCO and WALTHAM, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced that members of management will participate at the following investor conferences.

Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting
globenewswire.com16 October 2024 Sentiment: POSITIVE

SAN FRANCISCO and WALTHAM, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced an upcoming poster presentation at the American College of Allergy, Asthma & Immunology's (ACAAI) 2024 Annual Scientific Meeting, held in Boston from October 24-28, 2024. The company plans to present data up to 9 months from the ongoing Phase 1 clinical trial of APG777, a novel half-life extended anti-IL-13 antibody for the treatment for atopic dermatitis and other inflammatory diseases.

Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit
globenewswire.com12 September 2024 Sentiment: POSITIVE

SAN FRANCISCO and WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced that members of management, will participate in a fireside chat at the Stifel 2024 Immunology and Inflammation Summit on Wednesday, September 18, 2024 at 12:30 p.m. E.T. / 9:30 a.m. P.T.

Apogee Therapeutics: Infrequent Dosing Advantage In Biotech Play
seekingalpha.com18 June 2024 Sentiment: POSITIVE

Apogee Therapeutics stock has declined by 34% since a previous recommendation to buy, while the S&P 500 is up 7.7%. Apogee Therapeutics raised $420 million at $62/share, expanding their financial runway while advancing APG777 into Phase 2 trials. APG777, targeting atopic dermatitis and asthma, shows promise with less frequent dosing, aiming to compete with Sanofi's Dupixent.

Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why
Zacks Investment Research28 March 2024 Sentiment: POSITIVE

Apogee (APGE) surges 95.6% in a month after reporting positive interim results from its phase I study for APG777 to treat AD. The company plans to initiate a phase II study for the same indication.

Apogee Therapeutics: Success In Phase 1 Bodes Well For Continued APG777 Advancement
Seeking Alpha06 March 2024 Sentiment: POSITIVE

Apogee Therapeutics, Inc. positive interim results achieved from Phase 1 study of APG777 for Atopic Dermatitis and Phase 2 study initiation and additional data expected in 1st half of 2024 and 2025, respectively. Company has potential to overcome other biologic drug companies targeting patients with inflammatory disorders by improving drug exposure by a significant margin. The global atopic dermatitis market is expected to reach $19.1 billion by 2030.

Apogee Therapeutics' Innovative Leap In Atopic Dermatitis Management
Seeking Alpha05 March 2024 Sentiment: POSITIVE

Apogee Therapeutics' APG777 shows promising Phase 1 results for AD, with a notably long half-life potentially reducing dosing frequency. APG777's efficacy and safety profiles justify Phase 2 trials, aiming to outperform competitors like Sanofi's Dupixent by offering less frequent dosing. Apogee boasts a strong liquidity position, with a cash runway of around 64 months, indicating minimal short-term financing needs.

Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024
GlobeNewsWire04 March 2024 Sentiment: POSITIVE

SAN FRANCISCO and WALTHAM, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease, asthma and other inflammatory and immunology (I&I) indications, today announced it will report interim results from the Phase 1 APG777 healthy volunteer trial on Tuesday, March 5, 2024. Following the announcement, the Company will host a conference call and webcast at 7:00am ET to discuss the results.

Apogee Therapeutics: Potential To Target Autoimmune Disorders With Less Frequent Dosing
Seeking Alpha22 August 2023 Sentiment: POSITIVE

Review of Apogee Therapeutics' safety and pharmacokinetic data from phase 1 study using APG777 in healthy volunteers expected in mid-2024. Pending positive phase 1 safety and pharmacokinetic data using APG777, the initiation of a 16-week phase 2 study in atopic dermatitis patients is expected in 2024. The global atopic dermatitis market size is projected to reach $22.6 billion by 2031.

U.S. IPO Weekly Recap: July IPO Market Kicks Off With Sizable Biotechs
Seeking Alpha15 July 2023 Sentiment: POSITIVE

Following the Independence Day lull, the July IPO market warmed up with two sizable biotechs, joined by two blank check companies. Surf Air Mobility delayed its direct listing until later this month. In its second IPO attempt, Sagimet Biosciences priced a slightly upsized deal at the midpoint to raise $85 million at a $386 million market cap.

What type of business is Apogee Therapeutics?

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

What sector is Apogee Therapeutics in?

Apogee Therapeutics is in the Healthcare sector

What industry is Apogee Therapeutics in?

Apogee Therapeutics is in the Biotechnology industry

What country is Apogee Therapeutics from?

Apogee Therapeutics is headquartered in United States

When did Apogee Therapeutics go public?

Apogee Therapeutics initial public offering (IPO) was on 14 July 2023

What is Apogee Therapeutics website?

https://www.apogeetherapeutics.com

Is Apogee Therapeutics in the S&P 500?

No, Apogee Therapeutics is not included in the S&P 500 index

Is Apogee Therapeutics in the NASDAQ 100?

No, Apogee Therapeutics is not included in the NASDAQ 100 index

Is Apogee Therapeutics in the Dow Jones?

No, Apogee Therapeutics is not included in the Dow Jones index

When was Apogee Therapeutics the previous earnings report?

No data

When does Apogee Therapeutics earnings report?

The next expected earnings date for Apogee Therapeutics is 13 November 2024